Areas of Interest & Competitive Research Grants - Bristol Myers Squibb
Areas of Interest (AOI)
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| Immunology – TYK2 (deucravacitinib) | 22-Aug-22 | 19-Sep-22 | 28-Oct-22 |
| Immunology – Abatacept (Orencia) | 19-Sep-22 | 31-Oct-22 | 01-Dec-22 |
Orencia ISR Areas of Interest – RFP 2022-2023
Rheumatoid Arthritis:
- Therapeutic risk benefit profile of abatacept:
- Early intervention vs progressing to Rheumatoid Arthritis (RA); Characteristics of abatacept early responders, early remitters, sustained remitters and non-responders; Differential biology of ACPA+ and ACPA- abatacept responders
- At-risk RA, pre-RA, arthralgia, early RA:
- Patient subsets definition and characterization; Specific clinical endpoints and PROs; Criteria for early interception and intervention
- Combinational therapies:
- Safety; Patient subsets; Pathways
- Disease pathophysiology:
- Cell free DNA; Role of TLR7/8; Role of p38/MK2; Role of Type 1 interferon; Role of PAD4; Role of Tregs
Ankylosing Spondylitis (AS):
- Disease pathophysiology: Mechanism and biomarkers of anti-TNF resistance/response in AS; Role of autoantibodies; Role of TLR7/8; Role of p38/MK2; Role of BTK
- Specific clinical endpoints and PROs
Systemic Sclerosis:
- Disease pathophysiology: Role of autoantibodies; Role of TLR7/8; Role of p38/MK2; Role of BTK
- Specific clinical endpoints and PROs
Other rheumatologic diseases with high unmet medical needs (indication in submission will be "Immunoscience NOS" (not other specified)):
- Disease pathophysiology: Role of autoantibodies; Role of TLR7/8; Role of p38/MK2; Role of BTK
- Specific clinical endpoints and PROs
Out of Scope:
- Myositis
- Vasculitis
- Psoriatic Arthritis
- Lupus
- Sjögren's syndrome
- Common Variable Immunodeficiency
- Graft versus Host Disease
- Type 1 Diabetes
- COVID-19 vaccination
- COVID-19 infection
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here